Modular NDTVax™ Technology Platform

Creative Biolabs introduces the NDTVax™ platform, an advanced "triple-module" system designed to transform tumor mutanome data into high-potency preclinical vaccine candidates. By optimizing APC targeting and construct stability, we provide researchers with a structural edge in both oncology and infectious disease immunotherapy development.

Strategic Overview: Rationalizing Neoantigen Immunity

Exploiting Self-Nonself Discrimination

Successful cancer immunotherapy relies on the immune system's ability to distinguish "self" from "nonself." Tumor-Specific Neoantigens (TSAs), arising from non-synonymous somatic mutations, are exclusively absent from normal host tissues. This makes them ideal targets for avoiding off-target toxicity and bypassing central thymic tolerance. The NDTVax™ platform is strategically engineered to harness these neoantigens through a modular architecture that ensures maximum immunological impact.

The Triple-Module Logic: Our platform integrates three distinct functional blocks—Targeting, Dimerization, and Neoantigen modules. This synergy ensures that customized epitopes are not just delivered, but actively presented to the T-cell repertoire with enhanced magnitude and duration.

Core Structural Components:
Targeting Module: Mediates specific binding to Antigen-Presenting Cells (APCs), promoting construct internalization and DC maturation.
Dimerization Module: Increases construct avidity and structural stability, enhancing the efficiency of the cross-presentation pathway.
Neoantigen Module: A versatile payload section accommodating prioritized mutant epitopes tailored to individual tumor profiles.

Comprehensive Preclinical NDTVax™ Services

An Integrated Tiered Framework for High-Fidelity Preclinical Research

MUTANOME
MAPPING

WES-Driven Neoantigen Discovery & Ranking

We perform deep Whole Exome Sequencing (WES) and RNA-Seq analysis on paired tumor-normal samples. Our bioinformatics pipeline utilizes AI-driven filters to rank mutations based on variant allele frequency (VAF), expression levels, and MHC binding affinity.

Tumor/normal mutation calling

HLA-aware prioritization logic

CONSTRUCT
ENGINEERING

Multi-Format Modular Construct Engineering

We engineer modular vaccines as DNA vectors, IVT mRNA sequences, or purified recombinant protein complexes. Sequence architectures (linkers, spacers, codon usage) are optimized to ensure maximum in vivo stability and potency.

Custom linker optimization

DNA, RNA, & Protein formats

FUNCTIONAL
VERIFICATION

Targeting Integrity: In Vitro APC Assays

To validate the functional performance of the "Targeting Module," we offer high-fidelity cellular assays using primary or model APCs. We monitor construct uptake kinetics, internalization efficiency, and the maturation status of dendritic cells (DC).

APC uptake quantification

DC surface marker profiling

BIOLOGICAL
EFFICACY

In Vivo Proof-of-Concept & Efficacy Profiling

We provide full biological validation in preclinical tumor or infectious models. Studies include Tumor Growth Inhibition (TGI) assessment, cytokine profiling, and quantification of neoantigen-specific cytotoxic T-cell responses.

TGI & survival analysis

ELISpot & multi-parametric Flow

Highlight Platform Advantages

Dual-Model Suitability: Equally robust for cancer immunotherapy and infectious pathogen research.
Individualized Design: Rapid swapping of the "Neoantigen Module" payload to suit unique research profiles.
Superior Delivery: Targeted internalization significantly outperforms passive uptake in immune stimulation.

Concurrent Activation: Strategically stimulates cellular (T-cell) and humoral (B-cell) immune branches.
Scientific Expertise: Built upon a decade of expertise in preclinical antigen discovery and validation.
Multi-Payload Format: Flexibility to synthesize as DNA expression vectors, IVT RNA, or purified protein.

Preclinical NDTVax™ Development Workflow

1
Mutation Discovery: Subject-specific mutanome mapping via paired WES/RNA-Seq.
2
Modular Construction: Assembly of targeting, dimerization, and prioritized antigen blocks.

3
Functional Screening: In vitro verification of construct internalisation and DC activation.
4
Immune Validation: In vivo assessment of anti-tumor efficacy and memory clones.

Research Insight: Modular Neoepitope Dynamics

Case Study: WES-Driven Modular Vaccine Efficacy

In high-profile melanoma studies, the "modular" vaccine approach has demonstrated significant preclinical success. By targeting patient-specific neoepitopes identified via Whole Exome Sequencing (WES), these constructs induce high-magnitude T-cell responses that are protective and durable. Research indicates that modularized antigens are processed up to 5 times more efficiently than passive peptide mixtures.

Schematic of cancer antigen-specific cell destruction, tumor antigen subtypes, and neoantigen-based cancer therapy.

Fig.1 Cancer antigen-specific cell destruction, classification of tumor antigen subtypes, and neoantigen-directed cancer immunotherapy.^1,2

Precision Mapping: Utilization of WES identifies the 20 highest-ranking immunogenic mutations per subject, ensuring maximum mutanome coverage.
Immunological Impact: Induction of de novo neoantigen-specific T cells comprising up to 10% of total peripheral blood clones.
Sustained Memory: Vaccine-expanded clones have been observed to persist for over 2 years post-immunization in research subjects.
Safety Fidelity: Restricting activation to tumor-specific alterations minimizes off-target toxicity in healthy tissues.

Frequently Asked Questions

Traditional vaccines rely on passive antigen uptake by APCs, which is often inefficient. NDTVax™ includes a dedicated "Targeting Module" that actively binds to specific receptors on APCs, triggering internalization and maturation. Combined with the "Dimerization Module" for avidity, it drastically amplifies the intensity of the neoantigen presentation.

Yes. While neoantigens are foundational to oncology, the targeting and dimerization logic of the NDTVax™ platform is highly effective at enhancing immune recognition of viral or bacterial conserved epitopes, making it a versatile preclinical development engine.

NDTVax™ is platform-agnostic regarding payloads. We can assemble modular constructs as DNA expression vectors, IVT mRNA sequences, or high-purity recombinant protein complexes, depending on the requirements of your specific preclinical research model.

We utilize multi-parametric flow cytometry to analyze the upregulation of key maturation markers such as CD80, CD86, and MHC-II on the surface of dendritic cells following incubation with the modular constructs. Cytokine release (e.g., IL-12) is also monitored via ELISA or multiplex assays.

Timelines vary by complexity, but a standard cycle from sequencing data analysis to the completion of initial in vivo immunogenicity profiling typically spans 8-12 weeks. This includes neoepitope ranking, synthesis, and biological validation packages.